Drug Profile
DLX 105
Alternative Names: DLX-105; ESBA-105; Humanised single-chain (scFv) antibody directed against human TNF-alphaLatest Information Update: 11 May 2021
Price :
$50
*
At a glance
- Originator ESBATech
- Developer Delenex Therapeutics; ESBATech; Kuur Therapeutics
- Class Immunoglobulin fragments
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Behcet's syndrome; Crohn's disease; Dry eyes; Hidradenitis suppurativa; Ocular inflammation; Osteoarthritis; Plaque psoriasis; Uveitis
Most Recent Events
- 04 May 2021 Kuur Therapeutics has been acquired by Athenex
- 13 Mar 2020 Cell Medica is now called Kuur Therapeutics
- 09 Apr 2019 Novartis completed the spin-off of Alcon